Skip Navigation

Find a Doctor

Find a Researcher


Chien-Fu Hung, Ph.D.

Photo of Dr. Chien-Fu Hung, Ph.D.
  • Associate Professor of Pathology

Research Interests

Gene therapies; cancer vaccines; ovarian cancer immunotherapy; cancer immunology


Dr. Chien-Fu Hung is an associate professor of pathology and oncology and a professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine. He is a member of the Johns Hopkins Kimmel Cancer Center. His research focuses on the prevention and treatment of cervical and ovarian cancers.

His team is currently using an ascitogenic ovarian/peritoneal tumor model to investigate DNA vaccine strategies encoding ovarian tumor antigens identified by microarray and SAGE.

Dr. Hung earned his Ph.D. in molecular biology from the University of Illinois. He completed a fellowship in pharmacology at the University of Pennsylvania and a fellowship in pathology at the Johns Hopkins University.

He received a Young Investigator Award from the Alliance for Cancer Gene Therapy in 2004. more


  • Associate Professor of Pathology
  • Associate Professor of Gynecology and Obstetrics
  • Associate Professor of Oncology

Departments / Divisions

Centers & Institutes



  • Ph.D., University of Illinois (Urbana-Champaign) (Illinois) (1996)

Research & Publications

Research Summary

Dr. Hung's research focuses on developing vaccination strategies for the prevention and treatment of cervical and ovarian cancers.

His lab has developed several approaches to enhance immunologic responses against different cancers. Some of these involve 

  1. targeting antigen into dendritic cells (DCs), 
  2. targeting antigen into major histocompatability class I and II processing pathways, 
  3. enhancing intercellular spreading of antigen, and 
  4. combining antigen-specific immunotherapy with agents to limit angiogenesis.

Dr. Hung's research has led to the generation of clinical-grade vaccines for HPV-associated precancerous and cancerous lesions. Of special note, two of Dr. Hung's technologies (DNA vaccines based on HSP70 and calreticulin fusion technologies) have also been licensed and are under active development by biotechnology companies. Recently, Dr. Hung's lab has utilized annexin V (AnnV) as an immune checkpoint inhibitor and tumor-homing molecule for the treatment of cancer, as AnnV greatly enhances the immunogenicity and antitumor efficacy after chemoradiation.

Additionally, Dr. Hung has developed a novel universal immunotherapeutic molecule (Alb-Flt3L) by harnessing albumin's ability to extend serum half-life and preferential trafficking towards lymph nodes as well as the properties of Flt3L to potently expand cross-presenting DCs. Alb-Flt3L enhances immunological responses mediated by cross-presenting DCs and subsequently generates potent antigen-specific T and B cell responses.

Selected Publications

Yang, A, Jeang, J, Cheng, K, Cheng, T, Yang, B, Wu, TC, and Hung, CF. Current State in the Development of Candidate Therapeutic HPV Vaccines. Expert Rev Vaccines 2016; 15(8):989-1007.

Soong, RS., Anchoori R, Yang B, Yang A, Tseng SH, He L, Tsai YC, Roden RB, and Hung CF. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells. Oncotarget 2016; 7, 68489-68502

Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV and Emens LA. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. Hum Gene Ther. 2018; 29:614-625

Kang TH, Park JH, Yang A, Park HJ, Lee SE, Kim YS, Jang GY, Farmer, E, Park YM, Hung CF. AnnexinV as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment. (under revision in Nature Communications)

Lam B, Tseng SH, Cheng MA, Farmer E, Hung CF. The role of Albumin-Flt3L-induced cross-presenting dendritic cell expansion in antitumor immunity. (manuscript in preparation)

Is this you? Edit Profile
back to top button